ArticlePlant biotechnology journal2019
Plant-made E2 glycoprotein single-dose vaccine protects pigs against classical swine fever.
Article in Plant biotechnology journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 38 citations in OpenAlex.
- Efficacy Evaluation of an E2 Subunit Vaccine Against Highly Virulent Classical Swine Fever Virus Strain.Vaccines · 2025Article
- Enhancement of immune responses to classical swine fever virus E2 in mice by fusion or mixture with the porcine IL-28B.Applied microbiology and biotechnology · 2025Article
- Comprehensive evaluation of transgenic rice lines expressing CSFV E2 protein in genetic stability, environmental safety and field adaptation.Frontiers in plant science · 2025Article
- A Comprehensive Review of Our Understanding and Challenges of Viral Vaccines against Swine Pathogens.Viruses · 2024Review
- Development of a dual immunochromatographic test strip to detect E2 and EFrontiers in microbiology · 2024Article
- Plant-expressed Zika virus envelope protein elicited protective immunity against the Zika virus in immunocompetent mice.Scientific reports · 2023Article
- Rice-produced classical swine fever virus glycoprotein E2 with herringbone-dimer design to enhance immune responses.Plant biotechnology journal · 2023Article
- Review
- Article
- Review
- Review
- Research Progress and Challenges in Vaccine Development against Classical Swine Fever Virus.Viruses · 2021Review
- Future perspectives on swine viral vaccines: where are we headed?Porcine health management · 2021Review
- Recent Advances in the Diagnosis of Classical Swine Fever and Future Perspectives.Pathogens (Basel, Switzerland) · 2020Review
- Expression of recombinant classical swine fever virus E2 glycoprotein by endogenous Txnip promoter in stable transgenic CHO cells.Engineering in life sciences · 2020Article
- A classical swine fever virus E2 fusion protein produced in plants elicits a neutralizing humoral immune response in mice and pigs.Biotechnology letters · 2020Article
- A neutralizing monoclonal antibody-based competitive ELISA for classical swine fever C-strain post-vaccination monitoring.BMC veterinary research · 2020Article
- A Roadmap for the Molecular Farming of Viral Glycoprotein Vaccines: Engineering Glycosylation and Glycosylation-Directed Folding.Frontiers in plant science · 2020Review
- The potential efficacy of the E2-subunit vaccine to protect pigs against different genotypes of classical swine fever virus circulating in Vietnam.Clinical and experimental vaccine research · 2020Article
- Production of Human IFNγ Protein inViruses · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 1 country.
Funding
Abstract
Classical Swine Fever Virus (CSFV) causes classical swine fever, a highly contagious hemorrhagic fever affecting both feral and domesticated pigs. Outbreaks of CSF in Europe, Asia, Africa and South America had significant adverse impacts on animal health, food security and the pig industry. The disease is generally contained by prevention of exposure through import restrictions (e.g. banning import of live pigs and pork products), localized vaccination programmes and culling of infected or at-risk animals, often at very high cost. Current CSFV-modified live virus vaccines are protective, but do not allow differentiation of infected from vaccinated animals (DIVA), a critical aspect of disease surveillance programmes. Alternatively, first-generation subunit vaccines using the viral protein E2 allow for use of DIVA diagnostic tests, but are slow to induce a protective response, provide limited prevention of vertical transmission and may fail to block viral shedding. CSFV E2 subunit vaccines from a baculovirus/insect cell system have been developed for several vaccination campaigns in Europe and Asia. However, this expression system is considered expensive for a veterinary vaccine and is not ideal for wide-spread deployment. To address the issues of scalability, cost of production and immunogenicity, we have employed an Agrobacterium-mediated transient expression platform in Nicotiana benthamiana and formulated the purified antigen in novel oil-in-water emulsion adjuvants. We report the manufacturing of adjuvanted, plant-made CSFV E2 subunit vaccine. The vaccine provided complete protection in challenged pigs, even after single-dose vaccination, which was accompanied by strong virus neutralization antibody responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.